Sargent Investment Group, LLC Exelixis, Inc. Transaction History

Sargent Investment Group, LLC

$449 Million
Q1 2024

A detailed history of Sargent Investment Group, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Sargent Investment Group, LLC holds 278,470 shares of EXEL stock, worth $6.17 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares

278,470

Previous 296,350 6.03%

Holding current value

$6.17 Million

Previous $7.11 Million 7.05%

% of portfolio

1.47%

Previous 1.58%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$20.17 - $23.93 $360,639 - $427,868	-17,880 Reduced 6.03%	278,470 $6.61 Million
Q4 2023 Feb 05, 2024	SELL	$19.25 - $24.13 $31,666 - $39,693	-1,645 Reduced 0.55%	296,350 $7.11 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $115,382 - $137,804	-6,060 Reduced 1.99%	297,995 $6.51 Million
Q2 2023 Jul 31, 2023	SELL	$18.17 - $20.48 $170,798 - $192,512	-9,400 Reduced 3.0%	304,055 $5.81 Million
Q1 2023 May 02, 2023	BUY	$16.3 - $19.41 $374,818 - $446,332	22,995 Added 7.92%	313,455 $6.08 Million

Q4 2022 Jan 31, 2023	BUY	$14.96 - $17.39 $113,696 - $132,164	7,600 Added 2.69%	290,460 $4.66 Million
Q3 2022 Oct 26, 2022	BUY	$15.68 - $22.27 $332,024 - $471,567	21,175 Added 8.09%	282,860 $4.41 Million
Q2 2022 Jul 26, 2022	BUY	$17.44 - $23.16 $461,026 - $612,234	26,435 Added 11.24%	261,685 $5.45 Million
Q1 2022 May 06, 2022	SELL	$17.03 - $22.67 $1.04 Million - $1.39 Million	-61,170 Reduced 20.64%	235,250 $5.33 Million
Q4 2021 Feb 11, 2022	BUY	$15.84 - $21.88 $1.38 Million - $1.9 Million	86,850 Added 41.44%	296,420 $5.42 Million
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $4.48 Million - $5.81 Million	-274,850 Reduced 56.74%	209,570 $4.43 Million
Q2 2021 Aug 05, 2021	SELL	$17.95 - $25.56 $250,043 - $356,050	-13,930 Reduced 2.8%	484,420 $8.83 Million
Q1 2021 May 04, 2021	BUY	$20.53 - $25.22 $607,585 - $746,385	29,595 Added 6.31%	498,350 $11.3 Million
Q4 2020 Feb 10, 2021	SELL	$18.39 - $24.8 $1.04 Million - $1.4 Million	-56,330 Reduced 10.73%	468,755 $9.41 Million
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $91,774 - $119,613	-4,440 Reduced 0.84%	525,085 $12.8 Million
Q2 2020 Aug 11, 2020	SELL	$16.46 - $27.42 $778,228 - $1.3 Million	-47,280 Reduced 8.2%	529,525 $12.4 Million
Q1 2020 May 12, 2020	BUY	$14.46 - $21.8 $672,751 - $1.01 Million	46,525 Added 8.77%	576,805 $9.93 Million
Q4 2019 Feb 11, 2020	BUY	$15.15 - $18.89 $424,200 - $528,920	28,000 Added 5.57%	530,280 $9.34 Million
Q4 2019 Jan 30, 2020	BUY	$15.15 - $18.89 $555,399 - $692,507	36,660 Added 7.87%	502,280 $8.85 Million
Q3 2019 Oct 29, 2019	BUY	$17.68 - $22.65 $592,191 - $758,661	33,495 Added 7.75%	465,620 $8.23 Million
Q2 2019 Aug 12, 2019	BUY	$18.93 - $24.75 $31,897 - $41,703	1,685 Added 0.39%	432,125 $9.24 Million
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $709,324 - $896,064	36,190 Added 9.18%	430,440 $10.2 Million
Q4 2018 Feb 12, 2019	BUY	$13.65 - $21.8 $5.38 Million - $8.59 Million	394,250 New	394,250 $7.76 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.13B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.

Account

Sargent Investment Group, LLC Exelixis, Inc. Transaction History